AGP Picks
View all

St. Vincent & Grenadines Health Press
Provided by AGP

St. Vincent & Grenadines Health Press: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on St. Vincent & Grenadines Health Press.

August 2026

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31

September 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30

October 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on October 26, 2026

Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market
Oct. 26, 2026

Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market

Indeterminate GlobeNewswire
More Than 1 in 10 People Receive Medically Actionable Genetic Results Through 23andMe, Analysis of Nearly 6 Million Participants Finds
Oct. 26, 2026

More Than 1 in 10 People Receive Medically Actionable Genetic Results Through 23andMe, Analysis of Nearly 6 Million Participants Finds

Indeterminate GlobeNewswire
Avacta Group plc: Faridoxorubicin Treatment Results in Near Doubling of Progression-Free Survival and Clinically Meaningful Tumor Shrinkage in Most Patients with Salivary Gland Cancers
Oct. 26, 2026

Avacta Group plc: Faridoxorubicin Treatment Results in Near Doubling of Progression-Free Survival and Clinically Meaningful Tumor Shrinkage in Most Patients with Salivary Gland Cancers

Indeterminate GlobeNewswire
Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease
Oct. 26, 2026

Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease

Indeterminate GlobeNewswire
Ambros Therapeutics Announces Planned Interim Analysis of Phase 3 Clinical Trial Following FDA Feedback
Oct. 26, 2026

Ambros Therapeutics Announces Planned Interim Analysis of Phase 3 Clinical Trial Following FDA Feedback

Indeterminate GlobeNewswire
Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly
Oct. 26, 2026

Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly

Indeterminate GlobeNewswire
Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability
Oct. 26, 2026

Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability

Indeterminate GlobeNewswire
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Oct. 26, 2026

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Indeterminate GlobeNewswire
CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026
Oct. 26, 2026

CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026

Indeterminate GlobeNewswire
SS Innovations Showcases SSi Mantra Telesurgery Capabilities at October 2026 Conferences
Oct. 26, 2026

SS Innovations Showcases SSi Mantra Telesurgery Capabilities at October 2026 Conferences

Indeterminate GlobeNewswire
Weight Watchers Schedules Third Quarter 2026 Earnings Conference Call
Oct. 26, 2026

Weight Watchers Schedules Third Quarter 2026 Earnings Conference Call

Indeterminate GlobeNewswire
Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504
Oct. 26, 2026

Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504

Indeterminate GlobeNewswire
Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas
Oct. 26, 2026

Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas

Indeterminate GlobeNewswire
Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World’s First CGM System with No On-body Component
Oct. 26, 2026

Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World’s First CGM System with No On-body Component

Indeterminate GlobeNewswire
Affordable Pet Labs Launches Nationwide Validation Study of an At-Home Heartworm Test, and Invites Dog Owners in 52 Cities to Help
Oct. 26, 2026

Affordable Pet Labs Launches Nationwide Validation Study of an At-Home Heartworm Test, and Invites Dog Owners in 52 Cities to Help

Indeterminate GlobeNewswire
Stryker completes acquisition of ZuriMED to enhance its shoulder offering
Oct. 26, 2026

Stryker completes acquisition of ZuriMED to enhance its shoulder offering

Indeterminate GlobeNewswire
GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting
Oct. 26, 2026

GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting

Indeterminate GlobeNewswire
Certara to Report Third Quarter 2026 Financial Results on November 5th, 2026
Oct. 26, 2026

Certara to Report Third Quarter 2026 Financial Results on November 5th, 2026

Indeterminate GlobeNewswire
Seismic Therapeutic to Participate in Upcoming Investor Conferences
Oct. 26, 2026

Seismic Therapeutic to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire
Oncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer Signature
Oct. 26, 2026

Oncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer Signature

Indeterminate GlobeNewswire
Show More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

St. Vincent & Grenadines Health Press

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.